Literature DB >> 33204029

Mitochondrial oxidative phosphorylation in cutaneous melanoma.

Prakrit R Kumar1, Jamie A Moore1, Kristian M Bowles1,2, Stuart A Rushworth3, Marc D Moncrieff4,5.   

Abstract

The Warburg effect in tumour cells is associated with the upregulation of glycolysis to generate ATP, even under normoxic conditions and the presence of fully functioning mitochondria. However, scientific advances made over the past 15 years have reformed this perspective, demonstrating the importance of oxidative phosphorylation (OXPHOS) as well as glycolysis in malignant cells. The metabolic phenotypes in melanoma display heterogeneic dynamism (metabolic plasticity) between glycolysis and OXPHOS, conferring a survival advantage to adapt to harsh conditions and pathways of chemoresistance. Furthermore, the simultaneous upregulation of both OXPHOS and glycolysis (metabolic symbiosis) has been shown to be vital for melanoma progression. The tumour microenvironment (TME) has an essential supporting role in promoting progression, invasion and metastasis of melanoma. Mesenchymal stromal cells (MSCs) in the TME show a symbiotic relationship with melanoma, protecting tumour cells from apoptosis and conferring chemoresistance. With the significant role of OXPHOS in metabolic plasticity and symbiosis, our review outlines how mitochondrial transfer from MSCs to melanoma tumour cells plays a key role in melanoma progression and is the mechanism by which melanoma cells regain OXPHOS capacity even in the presence of mitochondrial mutations. The studies outlined in this review indicate that targeting mitochondrial trafficking is a potential novel therapeutic approach for this highly refractory disease.

Entities:  

Mesh:

Year:  2020        PMID: 33204029      PMCID: PMC7782830          DOI: 10.1038/s41416-020-01159-y

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  102 in total

1.  Melanoma: Molecular Pathogenesis and Therapeutic Management.

Authors:  Yuxin Liu; M Saeed Sheikh
Journal:  Mol Cell Pharmacol       Date:  2014

Review 2.  Cutaneous Melanoma-A Review in Detection, Staging, and Management.

Authors:  Rebecca I Hartman; Jennifer Y Lin
Journal:  Hematol Oncol Clin North Am       Date:  2019-02       Impact factor: 3.722

3.  Macrophages in skin melanoma-the key element in melanomagenesis.

Authors:  Malgorzata Pieniazek; Rafal Matkowski; Piotr Donizy
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

4.  Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories.

Authors:  Kyle J Foreman; Neal Marquez; Andrew Dolgert; Kai Fukutaki; Nancy Fullman; Madeline McGaughey; Martin A Pletcher; Amanda E Smith; Kendrick Tang; Chun-Wei Yuan; Jonathan C Brown; Joseph Friedman; Jiawei He; Kyle R Heuton; Mollie Holmberg; Disha J Patel; Patrick Reidy; Austin Carter; Kelly Cercy; Abigail Chapin; Dirk Douwes-Schultz; Tahvi Frank; Falko Goettsch; Patrick Y Liu; Vishnu Nandakumar; Marissa B Reitsma; Vince Reuter; Nafis Sadat; Reed J D Sorensen; Vinay Srinivasan; Rachel L Updike; Hunter York; Alan D Lopez; Rafael Lozano; Stephen S Lim; Ali H Mokdad; Stein Emil Vollset; Christopher J L Murray
Journal:  Lancet       Date:  2018-10-16       Impact factor: 79.321

5.  Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data.

Authors:  Marta Polkowska; Paweł Ekk-Cierniakowski; Edyta Czepielewska; Małgorzata Kozłowska-Wojciechowska
Journal:  Eur J Clin Pharmacol       Date:  2018-11-01       Impact factor: 2.953

Review 6.  BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.

Authors:  Francesco Spagnolo; Paola Ghiorzo; Laura Orgiano; Lorenza Pastorino; Virginia Picasso; Elena Tornari; Vincenzo Ottaviano; Paola Queirolo
Journal:  Onco Targets Ther       Date:  2015-01-16       Impact factor: 4.147

Review 7.  Current state of melanoma diagnosis and treatment.

Authors:  Lauren E Davis; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2019-08-01       Impact factor: 4.742

8.  Comprehensive Analysis of the Tumor Microenvironment in Cutaneous Melanoma associated with Immune Infiltration.

Authors:  Pan Wang; Xinyu Zhang; Nan Sun; Zhihong Zhao; Jie He
Journal:  J Cancer       Date:  2020-04-06       Impact factor: 4.207

Review 9.  WITHDRAWN: Systemic treatments for metastatic cutaneous melanoma.

Authors:  Tom Crosby; Reg Fish; Bernadette Coles; Malcolm Mason
Journal:  Cochrane Database Syst Rev       Date:  2018-02-07

Review 10.  Tumor microenvironment differences between primary tumor and brain metastases.

Authors:  Bernardo Cacho-Díaz; Donovan R García-Botello; Talia Wegman-Ostrosky; Gervith Reyes-Soto; Elizabeth Ortiz-Sánchez; Luis Alonso Herrera-Montalvo
Journal:  J Transl Med       Date:  2020-01-03       Impact factor: 5.531

View more
  12 in total

1.  The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study.

Authors:  Elena Lastraioli; Federico Alessandro Ruffinatti; Giacomo Bagni; Luca Visentin; Francesco di Costanzo; Luca Munaron; Annarosa Arcangeli
Journal:  Int J Mol Sci       Date:  2022-06-21       Impact factor: 6.208

Review 2.  Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation.

Authors:  Chelsea Schiliro; Bonnie L Firestein
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

3.  PGC-1α induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma.

Authors:  Prakrit R Kumar; Mona Saad; Charlotte Hellmich; Jayna J Mistry; Jamie A Moore; Shannon Conway; Christopher J Morris; Kristian M Bowles; Marc D Moncrieff; Stuart A Rushworth
Journal:  Br J Cancer       Date:  2022-03-26       Impact factor: 9.075

Review 4.  ROS Pleiotropy in Melanoma and Local Therapy with Physical Modalities.

Authors:  Sanjeev Kumar Sagwal; Sander Bekeschus
Journal:  Oxid Med Cell Longev       Date:  2021-11-03       Impact factor: 6.543

Review 5.  Mitochondrial Metabolism in Melanoma.

Authors:  Christina Huang; Rakan H Radi; Jack L Arbiser
Journal:  Cells       Date:  2021-11-16       Impact factor: 6.600

6.  Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors.

Authors:  Ramon Martinez; Weiliang Huang; Heather Buck; Samantha Rea; Amy E Defnet; Maureen A Kane; Paul Shapiro
Journal:  ACS Omega       Date:  2022-01-18

7.  Deep Visual Proteomics defines single-cell identity and heterogeneity.

Authors:  Andreas Mund; Fabian Coscia; András Kriston; Réka Hollandi; Ferenc Kovács; Andreas-David Brunner; Ede Migh; Lisa Schweizer; Alberto Santos; Michael Bzorek; Soraya Naimy; Lise Mette Rahbek-Gjerdrum; Beatrice Dyring-Andersen; Jutta Bulkescher; Claudia Lukas; Mark Adam Eckert; Ernst Lengyel; Christian Gnann; Emma Lundberg; Peter Horvath; Matthias Mann
Journal:  Nat Biotechnol       Date:  2022-05-19       Impact factor: 68.164

8.  Gene Instability-Related lncRNA Prognostic Model of Melanoma Patients via Machine Learning Strategy.

Authors:  Kexin Yan; Yutao Wang; Yining Shao; Ting Xiao
Journal:  J Oncol       Date:  2021-05-25       Impact factor: 4.375

Review 9.  Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications.

Authors:  Alice Indini; Francesco Grossi; Mario Mandalà; Daniela Taverna; Valentina Audrito
Journal:  Biomedicines       Date:  2021-05-26

Review 10.  Pathophysiological Integration of Metabolic Reprogramming in Breast Cancer.

Authors:  Roberto Corchado-Cobos; Natalia García-Sancha; Marina Mendiburu-Eliçabe; Aurora Gómez-Vecino; Alejandro Jiménez-Navas; Manuel Jesús Pérez-Baena; Marina Holgado-Madruga; Jian-Hua Mao; Javier Cañueto; Sonia Castillo-Lluva; Jesús Pérez-Losada
Journal:  Cancers (Basel)       Date:  2022-01-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.